title: Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al.
authors.forename: R
authors.initials: R
authors.lastname: Sperling
authors.forename: N
authors.initials: N
authors.lastname: Braunstein
authors.forename: J
authors.initials: J
authors.lastname: Melin
authors.forename: A
authors.initials: A
authors.lastname: Reicin
mesh_terms: D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib